Our results showing that FASN promotes carcinogenesis are also in agreement with studies on other types of cancer, showing that transgenic expression of FASN results in a significant increase in prostate intraepithelial neoplasia [41] and that pharmacological inhibition of FASN with Fasnall [42] or C75 [43] significantly delays tumor progression in neu-N mice, a model of mammary cancer. This evidence concerns the gene RBFOX3 and cancer.